Chemotherapy for malignant pleural mesothelioma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Opinion statement: All MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.

Original languageEnglish (US)
Pages (from-to)181-188
Number of pages8
JournalCurrent Treatment Options in Oncology
Volume12
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Folic Acid Antagonists
Drug Therapy
Platinum
Pemetrexed
Retreatment
Proxy
Combination Drug Therapy
Therapeutics
Randomized Controlled Trials
Quality of Life
Clinical Trials
Survival
Malignant Mesothelioma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Chemotherapy for malignant pleural mesothelioma. / Garland, Linda L.

In: Current Treatment Options in Oncology, Vol. 12, No. 2, 06.2011, p. 181-188.

Research output: Contribution to journalArticle

@article{6450f03401b84dfdb44941af8fcda9e8,
title = "Chemotherapy for malignant pleural mesothelioma",
abstract = "Opinion statement: All MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.",
author = "Garland, {Linda L}",
year = "2011",
month = "6",
doi = "10.1007/s11864-011-0152-6",
language = "English (US)",
volume = "12",
pages = "181--188",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Chemotherapy for malignant pleural mesothelioma

AU - Garland, Linda L

PY - 2011/6

Y1 - 2011/6

N2 - Opinion statement: All MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.

AB - Opinion statement: All MPM patients with a good performance status should be considered for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM patients remains an antifolate/platinum doublet, based on large, well powered randomized clinical trials that showed not only a survival benefit for antifolate/platinum regimens but also improvements in quality of life and/or symptoms. For less fit patients, single agents can be used as frontline therapy. In the second line setting, there is benefit from retreatment with single agent pemetrexed after prior exposure to that agent, as well as after exposure to other chemotherapeutic agents. Other single chemotherapy agents and combinations are viable options for fit patients who have had relatively long time to progression after their frontline therapy. Additionally, several prognostic scales designed for MPM (CALGB and EORTC) provide additional means to better select patients for frontline and second line chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79958044918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958044918&partnerID=8YFLogxK

U2 - 10.1007/s11864-011-0152-6

DO - 10.1007/s11864-011-0152-6

M3 - Article

C2 - 21468683

AN - SCOPUS:79958044918

VL - 12

SP - 181

EP - 188

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

ER -